- 0 Comments
- August 26, 2011
- by Randy Rozek
- Leave a comment
The type-2 diabetes drug Actos has been linked to a drastic increase in the rate of bladder cancer. Actos is taken orally in pill form. Actos works by helping the body reduce insulin resistance and utilize the body’s own naturally produced insulin or administered insulin. The active ingredient in Actos is Pioglitazone and it is found in the following diabetes drugs:
- ActoPlus Met
- ActoPlus Met XR
It has been estimated that in 2010, over 2.5 million people were prescribed some type of Pioglitazone-containing diabetes drug.
It has long been known that Actos increased the risk of cardiovascular problems, including heart attacks and heart failure. Post-market studies have also show that Actos use can lead to additional complications including the following:
- Actos Hepatitis
- Actos Liver Failure
- Inflammation of the Liver
- Elevated Liver Enzymes
- Bone Fracture (women greater than men)
However, recent studies have established that long-term, high dose Actos use increases the risk of bladder cancer by up to 40%. Men experienced a higher risk of getting bladder cancer from Actos than women. The release of this news resulted in France and Germany pulling Actos off the market. Unfortunately, in the United States all the FDA did was require Actos manufacturers to include a warning in the fine print on the package insert. See the FDA Actos Drug Safety Alert.
Actos and the other Pioglitazone-containing diabetes drugs are manufactured by Takeda Pharmaceutical Company and marketed in the United States by Eli Lilly Pharmaceuticals. It is estimated that over 20 million Americans have type-2 diabetes.
If you or a loved one have taken Actos, ActoPlus Met, ActoPlus Met XR or Duetac and have contracted Bladder Cancer, contact an experienced Wisconsin Actos Attorney.